Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Freeman TP"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 48
Tytuł:
Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019-2021: a repeat cross-sectional study.
Autorzy:
Wadsworth E; School of Public Health Sciences, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada. .; Canadian Centre on Substance Use and Addiction, 75 Albert St, Suite 500, Ottawa, ON, K1P 5E7, Canada. .; RAND Europe, Westbrook Centre, Milton Road, Cambridge, CB4 1YG, UK. .
Rynard V; School of Public Health Sciences, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
Driezen P; School of Public Health Sciences, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.; Department of Psychology, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
Freeman TP; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, BA2 7AY, UK.
Rychert M; SHORE & Whāriki Research Centre, College of Health, Massey University, Palmerston North, New Zealand.
Wilkins C; SHORE & Whāriki Research Centre, College of Health, Massey University, Palmerston North, New Zealand.
Hall W; National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Australia.
Gabrys R; Canadian Centre on Substance Use and Addiction, 75 Albert St, Suite 500, Ottawa, ON, K1P 5E7, Canada.
Hammond D; School of Public Health Sciences, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Feb 17; Vol. 20 (1), pp. 19. Date of Electronic Publication: 2023 Feb 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cannabis*
Marijuana Use*
Humans ; Cross-Sectional Studies ; Canada ; Legislation, Drug
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Acceptability of integrating smoking cessation treatment into routine care for people with mental illness: A qualitative study.
Autorzy:
Sawyer K; Department of Psychology, Addiction and Mental Health Group, University of Bath, Bath, UK.
Fredman Stein K; Department of Psychology, Addiction and Mental Health Group, University of Bath, Bath, UK.
Jacobsen P; Department of Psychology, Addiction and Mental Health Group, Bath Centre for Mindfulness and Compassion, University of Bath, Bath, UK.
Freeman TP; Department of Psychology, Addiction and Mental Health Group, University of Bath, Bath, UK.
Blackwell AKM; Department of Psychology, Addiction and Mental Health Group, University of Bath, Bath, UK.
Metcalfe C; Bristol Randomised Trials Collaboration, Population Health Sciences, Bristol Medical School, Bristol, UK.
Kessler D; Department of Population Health Sciences, Bristol Medical School, Centre for Academic Primary Care, University of Bristol, Bristol, UK.
Munafò MR; MRC Integrative Epidemiology Unit, School of Psychological Science, University of Bristol, Bristol, UK.
Aveyard P; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Taylor GMJ; Department of Psychology, Addiction and Mental Health Group, University of Bath, Bath, UK.
Pokaż więcej
Źródło:
Health expectations : an international journal of public participation in health care and health policy [Health Expect] 2023 Feb; Vol. 26 (1), pp. 108-118. Date of Electronic Publication: 2022 Oct 12.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Smoking Cessation*/psychology
Mental Disorders*/therapy
Mental Disorders*/psychology
Humans ; Female ; Male ; Smoking ; Mental Health ; Psychotherapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
Autorzy:
Lees R; Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK. .
Hines LA; Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK.
Hindocha C; Clinical Psychopharmacology Unit, UCL, London, UK.
Baio G; Department of Statistical Science, UCL, London, UK.
Shaban NDC; University of Oxford, Oxford, UK.
Stothart G; Department of Psychology, University of Bath, Bath, UK.
Mofeez A; Pain Management Centre, National Hospital for Neurology and Neurosurgery, UCLH, London, UK.
Morgan CJA; Psychopharmacology and Addiction Research Centre, University of Exeter, Exeter, UK.
Curran HV; Clinical Psychopharmacology Unit, UCL, London, UK.
Freeman TP; Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2023 Feb; Vol. 240 (2), pp. 337-346. Date of Electronic Publication: 2023 Jan 04.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Cannabidiol*/pharmacology
Cannabidiol*/therapeutic use
Marijuana Abuse*/complications
Marijuana Abuse*/drug therapy
Hallucinogens*/pharmacology
Substance-Related Disorders*/drug therapy
Cannabis*/adverse effects
Humans ; Cognition ; Double-Blind Method
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
Autorzy:
Craft S; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Dunn M; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Vidler D; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Officer J; Scottish Police Authority Forensic Services, Edinburgh, UK.
Blagbrough IS; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
Pudney CR; Department of Biology and Biochemistry, University of Bath, Bath, UK.
Henderson G; School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Abouzeid A; Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, Blackpool, UK.
Dargan PI; Guy's and St Thomas' NHS Foundation Trust, London, UK.
Eddleston M; Royal Infirmary of Edinburgh, Edinburgh, UK.
Cooper J; Aberdeen Royal Infirmary, Aberdeen, UK.
Hill SL; Newcastle Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle, UK.
Roper C; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Freeman TP; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Thomas SHL; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Nov; Vol. 117 (11), pp. 2899-2906. Date of Electronic Publication: 2022 Jun 19.
Typ publikacji:
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Cannabinoid Receptor Agonists*/adverse effects
Personality*
Chromatography, Liquid ; Female ; Hospitals ; Humans ; Male ; United Kingdom/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Response to Bahji et al.: Limitations of the available evidence that restrict our interpretation of the transition from cannabis to opioid use.
Autorzy:
Wilson J; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Mills KL; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Freeman TP; Addiction and Mental Health Group (AIM), University of Bath, Bath, UK.
Sunderland M; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Visontay R; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Marel C; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Oct; Vol. 117 (10), pp. 2754-2755. Date of Electronic Publication: 2022 Jul 08.
Typ publikacji:
Letter; Comment
MeSH Terms:
Cannabis*
Hallucinogens*
Opioid-Related Disorders*/drug therapy
Analgesics ; Analgesics, Opioid/therapeutic use ; Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The iCannTookit: a consensus-based, flexible framework for measuring contemporary cannabis use.
Autorzy:
Lorenzetti V; Neuroscience of Addiction and Mental Health Program, the Healthy Brain and Mind Research Centre, School of Behavioural and Health Sciences, Faculty of Health, Australian Catholic University, Melbourne, Australia.
Hindocha C; Clinical Psychopharmacology Unit, University College London, London, UK.
Petrilli K; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Griffiths P; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Portugal.
Brown J; Behavioural Science and Health Institute of Epidemiology and Health, University College London, London, UK.
Castillo-Carniglia Á; Society and Health Research Center and School of Public Health, Universidad Mayor, Chile.; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Caulkins JP; Carnegie Mellon University Heinz College, Pittsburgh, PA, USA.
Englund A; Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
El Sohly MA; National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, USA.; Department Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, USA.
Gage SH; Department of Psychology, Institute of Population Health, University of Liverpool, Liverpool, UK.
Groshkova T; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Portugal.
Gual A; Psychiatry Department, Neurosciences Institute, Hospital Clinic, IDIBAPS, RTA, Barcelona, Spain.
Hammond D; School of Public Health Sciences, University of Waterloo, Waterloo, ON, Canada.
Lawn W; Clinical Psychopharmacology Unit, University College London, London, UK.
López-Pelayo H; Psychiatry Department, Neurosciences Institute, Hospital Clinic, IDIBAPS, RTA, Barcelona, Spain.
Manthey J; Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.; Center for Interdisciplinary Addiction Research, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mokrysz C; Clinical Psychopharmacology Unit, University College London, London, UK.
Liccardo Pacula R; USC Sol Price School of Public Policy, USC Leonard D. Schaeffer Center for Health Policy and Economics, Los Angeles, CA, USA.
van Laar M; Trimbos Institute, Utrecht, the Netherlands.
Vandrey R; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wadsworth E; School of Public Health Sciences, University of Waterloo, Waterloo, ON, Canada.
Winstock A; Behavioural Science and Health Institute of Epidemiology and Health, University College London, London, UK.; Global Drug Survey, London, UK.
Hall W; National Addiction Centre, King's College London, London, UK.; National Centre for Youth Substance Use Research, The University of Queensland, Australia.
Curran HV; Clinical Psychopharmacology Unit, University College London, London, UK.
Freeman TP; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Sep; Vol. 117 (9), pp. 2558-2560. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Letter; Comment
MeSH Terms:
Cannabis*
Hallucinogens*
Analgesics ; Cannabinoid Receptor Agonists ; Consensus ; Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evidence from naturalistic studies can be strengthened by triangulation.
Autorzy:
Freeman TP; Addiction and Mental Health Group (AIM), University of Bath, Bath, UK.
Scott J; Addiction and Mental Health Group (AIM), University of Bath, Bath, UK.
Taylor GMJ; Addiction and Mental Health Group (AIM), University of Bath, Bath, UK.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Aug; Vol. 117 (8), pp. 2141-2142. Date of Electronic Publication: 2022 Apr 17.
Typ publikacji:
Journal Article
MeSH Terms:
Research Design*
Humans ; Reproducibility of Results
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Correction to: The CannTeen study: verbal episodic memory, spatial working memory, and response inhibition in adolescent and adult cannabis users and age‑matched controls.
Autorzy:
Lawn W; Clinical Psychopharmacology Unit, University College London, London, UK. .; Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .; Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .
Fernandez-Vinson N; Clinical Psychopharmacology Unit, University College London, London, UK.; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Mokrysz C; Clinical Psychopharmacology Unit, University College London, London, UK.
Hogg G; Clinical Psychopharmacology Unit, University College London, London, UK.
Lees R; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Trinci K; Clinical Psychopharmacology Unit, University College London, London, UK.
Petrilli K; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Borissova A; Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; NIHR University College London Hospitals Biomedical Research Centre, University College Hospital, London, UK.
Ofori S; Clinical Psychopharmacology Unit, University College London, London, UK.
Waters S; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
Michór P; School of Life Sciences, University of Warwick, Coventry, UK.
Wall MB; Clinical Psychopharmacology Unit, University College London, London, UK.; Invicro London, Hammersmith Hospital, Burlington Danes Building, Du Cane Road, London, UK.
Freeman TP; Clinical Psychopharmacology Unit, University College London, London, UK.; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Curran HV; Clinical Psychopharmacology Unit, University College London, London, UK.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 Jul; Vol. 239 (7), pp. 2371.
Typ publikacji:
Published Erratum
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The iCannToolkit: a tool to embrace measurement of medicinal and non-medicinal cannabis use across licit, illicit and cross-cultural settings.
Autorzy:
Lorenzetti V; Neuroscience of Addiction and Mental Health Program, the Healthy Brain and Mind Research Centre, School of Behavioural and Health Sciences, Faculty of Health, Australian Catholic University, Melbourne, Australia.
Hindocha C; Clinical Psychopharmacology Unit, University College London, London, UK.
Petrilli K; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, Somerset, UK.
Griffiths P; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Portugal.
Brown J; Department of Behavioural Science and Health, Institute of Epidemiology & Health Care, University College London, London, UK.
Castillo-Carniglia Á; Society and Health Research Center, Universidad Mayor, Millennium Nucleus for the Evaluation and Analysis of Drug Policies (nDP), and Millennium Nucleus on Sociomedicine (SocioMed), Chile.; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Caulkins JP; Carnegie Mellon University Heinz College, Pittsburgh, PA, USA.
Englund A; Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King''s College London, London, UK.
ElSohly MA; National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, Mississippi, USA.; Department Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, USA.
Gage SH; Department of Psychology, Institute of Population Health, University of Liverpool, Liverpool, UK.
Groshkova T; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Portugal.
Gual A; Addictions Research Group. Psychiatry Department, Neurosciences Institute. Hospital Clínic. IDIBAPS. RTA. Barcelona, Spain.
Hammond D; School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.
Lawn W; Clinical Psychopharmacology Unit, University College London, London, UK.
López-Pelayo H; Addictions Research Group. Psychiatry Department, Neurosciences Institute. Hospital Clínic. IDIBAPS. RTA. Barcelona, Spain.
Manthey J; Center for Interdisciplinary Addiction Research, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department of Psychiatry, Medical Faculty, University of Leipzig, Leipzig, Germany.
Mokrysz C; Clinical Psychopharmacology Unit, University College London, London, UK.
Liccardo Pacula R; USC Sol Price School of Public Policy, USC Leonard D. Schaeffer Center for Health Policy & Economics, California, Los Angeles, USA.
van Laar M; Trimbos Institute, Utrecht, The Netherlands.
Vandrey R; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wadsworth E; School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.
Winstock A; Department of Behavioural Science and Health, Institute of Epidemiology & Health Care, University College London, London, UK.; Global Drug Survey, London, UK.
Hall W; Queensland Alliance for Environmental Health Sciences, The University of Queensland, Australia.; National Centre for Youth Substance Use Research, The University of Queensland, Australia.
Curran HV; Clinical Psychopharmacology Unit, University College London, London, UK.
Freeman TP; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, Somerset, UK.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Jun; Vol. 117 (6), pp. 1523-1525. Date of Electronic Publication: 2022 Mar 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Cannabis*
Medical Marijuana*
Cross-Cultural Comparison ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.
Autorzy:
Lorenzetti V; Neuroscience of Addiction and Mental Health Program, the Healthy Brain and Mind Research Centre, School of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, Melbourne, Australia.
Hindocha C; Clinical Psychopharmacology Unit (CPU), University College London, London, UK.
Petrilli K; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Griffiths P; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
Brown J; Behavioural Science and Health Institute of Epidemiology and Health, University College London, London, UK.
Castillo-Carniglia Á; Society and Health Research Center and School of Public Health, Universidad Mayor, Santiago, Chile.; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Caulkins JP; Carnegie Mellon University Heinz College, Pittsburgh, PA, USA.
Englund A; Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK.; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
ElSohly MA; National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, USA.; Department Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, USA.
Gage SH; Department of Psychology, Institute of Population Health, University of Liverpool, Liverpool, UK.
Groshkova T; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
Gual A; Psychiatry Department, Neurosciences Institute, Hospital Clínic, IDIBAPS, RTA, Barcelona, Spain.
Hammond D; School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada.
Lawn W; Clinical Psychopharmacology Unit (CPU), University College London, London, UK.; Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK.
López-Pelayo H; Psychiatry Department, Neurosciences Institute, Hospital Clínic, IDIBAPS, RTA, Barcelona, Spain.
Manthey J; Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.; Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.
Mokrysz C; Clinical Psychopharmacology Unit (CPU), University College London, London, UK.
Pacula RL; USC Sol Price School of Public Policy, USC Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, CA, USA.
van Laar M; Trimbos Institute, Utrecht, The Netherlands.
Vandrey R; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wadsworth E; School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada.
Winstock A; Behavioural Science and Health Institute of Epidemiology and Health, University College London, London, UK.; Global Drug Survey, London, UK.
Hall W; National Addiction Centre, King's College London, London, UK.; National Centre for Youth Substance Use Research, The University of Queensland, Brisbane, Australia.
Curran HV; Clinical Psychopharmacology Unit (CPU), University College London, London, UK.
Freeman TP; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Jun; Vol. 117 (6), pp. 1510-1517. Date of Electronic Publication: 2021 Oct 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cannabis*
Consensus ; Costs and Cost Analysis ; Humans ; Self Report
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
Autorzy:
Craft S; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK. .; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .
Ferris JA; Centre for Health Services Research, University of Queensland, QLD, Queensland, Brisbane, Australia.
Barratt MJ; Social and Global Studies Centre and Digital Ethnography Research Centre, RMIT University, Victoria, Melbourne, Australia.; National Drug and Alcohol Research Centre, University of New South Wales Sydney, New South Wales, Sydney, Australia.
Maier LJ; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, USA.
Lynskey MT; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Winstock AR; Global Drug Survey Ltd, London, UK.; Institute of Epidemiology and Health Care, University College London, London, UK.
Freeman TP; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 May; Vol. 239 (5), pp. 1349-1357. Date of Electronic Publication: 2021 Sep 17.
Typ publikacji:
Journal Article
MeSH Terms:
Cannabis*
Hallucinogens*
Substance Withdrawal Syndrome*
Analgesics ; Cannabinoid Receptor Agonists/adverse effects ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.
Autorzy:
Bloomfield MAP; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK. .; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK. .; Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK. .; NIHR University College Hospitals London Biomedical Research Centre, University College London, London, UK. .; The Traumatic Stress Clinic, St Pancras Hospital, Camden and Islington NHS Foundation Trust, London, UK. .; National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK. .
Yamamori Y; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK.; Institute of Cognitive Neuroscience, University College London, London, UK.
Hindocha C; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK.; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.; NIHR University College Hospitals London Biomedical Research Centre, University College London, London, UK.
Jones APM; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK.; Medical Sciences Division, University of Oxford, Oxford, UK.
Yim JLL; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK.; Institute of Cognitive Neuroscience, University College London, London, UK.; King's Clinical Trials Unit, King's College London, London, UK.
Walker HR; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK.
Statton B; Medical Research Council, London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.
Wall MB; Invicro, Hammersmith Hospital, London, UK.
Lees RH; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Howes OD; Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.; Psychosis Studies, King's College London, London, UK.
Curran VH; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.; NIHR University College Hospitals London Biomedical Research Centre, University College London, London, UK.
Roiser JP; Institute of Cognitive Neuroscience, University College London, London, UK.
Freeman TP; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, Maple House, Tottenham Court Road, London, W1T 7NF, UK.; Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.; National Addiction Centre, King's College London, London, UK.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 May; Vol. 239 (5), pp. 1539-1549. Date of Electronic Publication: 2022 Apr 21.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Anti-Anxiety Agents*/pharmacology
Cannabidiol*
Anxiety/psychology ; Anxiety Disorders/drug therapy ; Double-Blind Method ; Emotions ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The CannTeen study: verbal episodic memory, spatial working memory, and response inhibition in adolescent and adult cannabis users and age-matched controls.
Autorzy:
Lawn W; Clinical Psychopharmacology Unit, University College London, London, UK. .; Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .; Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .
Fernandez-Vinson N; Clinical Psychopharmacology Unit, University College London, London, UK.; Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Mokrysz C; Clinical Psychopharmacology Unit, University College London, London, UK.
Hogg G; Clinical Psychopharmacology Unit, University College London, London, UK.
Lees R; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Trinci K; Clinical Psychopharmacology Unit, University College London, London, UK.
Petrilli K; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Borissova A; Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; NIHR University College London Hospitals Biomedical Research Centre, University College Hospital, London, UK.
Ofori S; Clinical Psychopharmacology Unit, University College London, London, UK.
Waters S; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
Michór P; School of Life Sciences, University of Warwick, Coventry, UK.
Wall MB; Clinical Psychopharmacology Unit, University College London, London, UK.; Invicro London, Hammersmith Hospital, Burlington Danes Building, Du Cane Road, London, UK.
Freeman TP; Clinical Psychopharmacology Unit, University College London, London, UK.; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
Curran HV; Clinical Psychopharmacology Unit, University College London, London, UK.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 May; Vol. 239 (5), pp. 1629-1641. Date of Electronic Publication: 2022 Apr 29.
Typ publikacji:
Journal Article
MeSH Terms:
Cannabis*
Memory, Episodic*
Adolescent ; Adult ; Bayes Theorem ; Cognition ; Cross-Sectional Studies ; Humans ; Memory, Short-Term/physiology ; Neuropsychological Tests
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence.
Autorzy:
Wilson J; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Mills K; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Freeman TP; Addiction and Mental Health Group (AIM), University of Bath, Bath, UK.
Sunderland M; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Visontay R; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Marel C; The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Feb; Vol. 117 (2), pp. 284-298. Date of Electronic Publication: 2021 Jul 15.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms:
Cannabis*
Hallucinogens*
Marijuana Abuse*/epidemiology
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Analgesics, Opioid/therapeutic use ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 48

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies